OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Choueiri on Initial Efficacy Data With NKT2152 in Pretreated ccRCC

September 26th 2024

Toni K. Choueiri, MD, discusses early findings from a phase 1/2 trial evaluating NKT2152 in previously-treated advanced clear cell renal cell carcinoma.

Dr Armenian on Improving Outcomes and Reducing AEs in Pediatric Oncology

September 26th 2024

Saro H. Armenian, DO, MPH, discusses treatment advancements that have helped reduce long-term adverse effects for patients in pediatric oncology.

Dr McKean on the Efficacy of Fianlimab Plus Cemiplimab in Advanced Melanoma

September 26th 2024

Meredith McKean, MD, discusses the efficacy of fianlimab given in combination with cemiplimab for patients with advanced melanoma.

Dr Ng on the Addition of Vitamin D to Bevacizumab Plus Chemotherapy in mCRC

September 26th 2024

Kimmie Ng, MD, MPH, discusses the addition of vitamin D to standard chemotherapy plus bevacizumab in patients with untreated metastatic colorectal cancer.

Dr Partridge on Unique Treatment Challenges for Young Patients with ER+/Node-Positive Breast Cancer

September 25th 2024

Ann H. Partridge, MD, MPH, discusses unique challenges associated with very young patients who have ER+/node-positive breast cancer.

Dr Strickler on the Safety and Efficacy of Telisotuzumab Adizutecan in Gastric/GEJ Cancer

September 25th 2024

John H. Strickler, MD, discusses the efficacy and safety of telisotuzumab adizutecan in patients with MET gene–amplified gastric/GEJ cancer.

Dr Aggarwal on Data for CAN-2409 Plus Valacyclovir and Continued ICIs in NSCLC

September 25th 2024

Charu Aggarwal, MD, MPH, FASCO, on data for CAN-2409 plus valacyclovir with continued immune checkpoint inhibitors in advanced non–small cell lung cancer.

Dr Saad on the Efficacy and Safety of Darolutamide Plus ADT in mHSPC

September 25th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy findings from the ARANOTE trial in patients with metastatic hormone-sensitive prostate cancer.

Dr Armenian on Challenges With Transitioning from Pediatric to Adult Cancer Care

September 25th 2024

Saro H. Armenian, DO, MPH, discusses the difficulties that patients face when transitioning from pediatric to adult cancer care, highlighting unmet needs.

Dr Morgans on Recent Adjustments to Medicare Part D to Improve Treatment Access in Prostate Cancer

September 24th 2024

Alicia Morgans, MD, MPH, discusses recent adjustments to Medicare Part D rules, emphasizing their positive impact on out-of-pocket costs for patients with prostate cancer.

Dr Berchuck on Detecting PSMA Expression With a Novel Epigenomic Liquid Biopsy in mCRPC

September 24th 2024

Jacob E. Berchuck, MD, discusses the use of a novel epigenomic liquid biopsy platform to noninvasively detect PSMA expression in mCRPC.

Dr Kaklamani on the Role of Adjuvant Ribociclib in Early-Stage HR+/HER2– Breast Cancer

September 24th 2024

Virginia Kaklamani, MD, discusses the optimal role for adjuvant ribociclib alongside endocrine therapy in early-stage HR+/HER2– breast cancer.

Dr Banerjee on Deciding Between CAR T-Cell Therapy and Bispecific Antibodies in Myeloma

September 24th 2024

Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.

Dr Drakaki on a Case Study in ALK+ Refractory Metastatic RCC

September 24th 2024

Alexandra Drakaki, MD, PhD, discusses a case study of a patient with refractory metastatic renal cell carcinoma harboring an ALK rearrangement.

Dr Amanam on Criteria for Selecting a JAK Inhibitor in Myelofibrosis

September 23rd 2024

Idoroenyi Amanam, MD, discusses criteria for selecting patients with myelofibrosis who may benefit from JAK inhibitors.

Dr Singer on the Lack of Clinical Benefit for Immunotherapy Rechallenge in Advanced RCC

September 23rd 2024

Adam Singer, MD, PhD, discusses the lack of clinical benefit for sequential immunotherapy in advanced renal cell carcinoma.

Dr Chambers on Access, Toxicities, and Long-term Considerations for PARP Inhibitors in Ovarian Cancer

September 23rd 2024

Laura J. Chambers, DO, discusses challenges patients with ovarian cancer face in accessing PARP inhibitor treatment.

Dr Tang on the Current Role for Radiation Therapy in Advanced RCC

September 23rd 2024

Chad Tang, MD, discusses the potential role for radiation therapy in advanced renal cell carcinoma.

Dr Lim on the Significance of the FDA Approval of Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 23rd 2024

Bora Lim, MD, discusses the FDA approval of adjuvant ribociclib plus an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer.

Dr Ye on Early Efficacy Data for BL-B01D1 in Metastatic Urothelial Carcinoma

September 20th 2024

Dingwei Ye, MD, PhD, discusses the initial efficacy and safety of BL-B01D1 in locally advanced or metastatic urothelial carcinoma.